Clin2
NCT07684326Possibly a fitRecruiting

Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)

Ascites Hepatic

Treatments studied

Part of Digestive system clinical trials.

This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
52 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older with liver cirrhosis and fluid buildup in your abdomen (ascites) that has required you to be in the hospital, now or in the past.
  • Your liver disease is not too advanced (Child-Pugh score below 12 and MELD score 25 or less).
  • You do not have a history of very low blood sugar or diabetic ketoacidosis.
  • Your blood pressure is 90/60 or higher, and you do not need more than one strong blood-pressure raising medicine daily.
  • You have not had more than 2 urinary tract infections in the last 6 months, and you have no structural problems in your urinary tract (like blockages or defects).
  • You are not pregnant, breastfeeding, allergic to dapagliflozin, and your kidney function is good (eGFR 30 or higher).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06783166Recruiting· Phase 2/Phase 3
Comparing two medications for acute heart failure with fluid buildup

This trial tests if dapagliflozin or acetazolamide works better for people hospitalized with heart failure who have extra fluid in their body (congestion). The study will compare how well each medication helps remove fluid when used with standard IV diuretics.

Al Mansurah
NCT06897605Recruiting· Phase 2
Dapagliflozin for anemia in kidney disease

This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.

Al Mansurah
NCT06919523Not yet recruiting· Phase 2
Dapagliflozin for hard-to-treat ascites in cirrhosis

This trial tests whether dapagliflozin, a diabetes medicine that helps remove extra fluid through urine, can reduce fluid buildup in the belly (ascites) that doesn't improve with standard treatments. It is for people with advanced liver disease whose ascites keeps coming back quickly.

NCT05726032Recruiting· Phase 2
Empagliflozin for fluid buildup from cirrhosis

This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.

New Haven, Connecticut
NCT06398977Recruiting
Dapagliflozin to protect kidney function in dialysis patients

This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.

Chengdu, Sichuan
NCT06762964Recruiting· Phase 2
Dapagliflozin for Failing Fontan Circulation

This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.

Rochester, Minnesota

Hear when a new Ascites Hepatic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.